Form 4: CareDx Director Awarded 27,453 Restricted Stock Units

CareDx, Inc. Director Suresh Gunasekaran was granted 27,453 restricted stock units, vesting over three years.

Summary

• Suresh Gunasekaran, a Director of CareDx, Inc. (CDNA), was granted 27,453 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was October 22, 2025.
• Each RSU represents a contingent right to receive one share of CareDx's Common Stock upon settlement for no consideration.
• The RSUs will vest in equal annual installments, with 100% vesting on the third anniversary of October 22, 2025.
• Vesting is contingent upon Mr. Gunasekaran's continuous service to the company on each applicable vesting date.
• Following this transaction, Mr. Gunasekaran beneficially owns 27,453 shares directly.

Sentiment

Score: 6

Explanation: The filing reports a routine compensation grant to a director, which is generally viewed as a neutral to slightly positive event as it aligns management interests with shareholders, without indicating any significant operational or financial changes.

Positives

• The grant of Restricted Stock Units aligns the director's long-term interests with those of the shareholders, promoting sustained performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members in publicly traded companies.

Negatives

• The future issuance of shares upon vesting of these RSUs could lead to minor dilution for existing shareholders.

Risks

• The vesting of the RSUs is subject to the reporting person's continuous service, meaning the full award may not be realized if service ceases prematurely.

Future Outlook

The vesting schedule of the RSUs over three years indicates an expectation of continued service from Director Suresh Gunasekaran, aligning his incentives with the company's long-term performance.

Industry Context

The grant of restricted stock units to directors is a common and widely accepted practice in the biotechnology and diagnostics industry, as well as across publicly traded companies generally. This form of compensation is used to attract and retain experienced board members and to align their financial interests with the long-term success and shareholder value of the company.

Comparison to Industry Standards

• The grant of restricted stock units to directors is a common practice across publicly traded companies.
• This form of equity compensation, with a multi-year vesting schedule, is standard in the biotechnology and diagnostics sector, similar to practices observed at companies like Illumina (ILMN) or Guardant Health (GH).
• The purpose is to align director incentives with long-term shareholder value, a global benchmark for corporate governance.

Related Party Transactions

• Grant of 27,453 Restricted Stock Units to Suresh Gunasekaran, a Director of CareDx, Inc., as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon RSU vesting, but also improved alignment of director's interests with long-term shareholder value.
• Employees: No direct impact mentioned, but reflects standard compensation practices for leadership.

Next Steps

• Annual vesting of RSUs on October 22, 2026, October 22, 2027, and October 22, 2028, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing reports a routine compensation grant to a director and does not contain information that would materially alter the investment thesis for CareDx, Inc. It is a standard practice to align director incentives with shareholder interests, and as such, it does not warrant a change in investment recommendation.

Keywords

CareDx, CDNA, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Equity Grant, Suresh Gunasekaran, SEC Form 4